Congressional Research Service Reports - 146 Matching Results

Search Results

Results: 1 - 50 next
Medicare: Prescription Drug Proposals
This report provides an overview of the President’s plan and the legislation introduced to date in the 106th Congress. It
Medicare: Selected Prescription Drug Proposals
Report on selected prescription drug proposals in the Medicare program, including a cost benefits analysis, summary of proposals, background of the issues, and more.
Medicare: Side-by-Side Comparison of Selected Prescription Drug Bills
Report comparing prescription drug bills in the Medicare program, including an examination of the covered population, benefits, deductibles, premiums, and more.
Medicare: Beneficiary Cost-Sharing Under Prescription Drug Legislation
This report provides an analysis of how the cost-sharing and premium provisions under the Prescription Drug and Medicare Improvement Act of 2003 (S. 1) and the Medicare Prescription Drug and Modernization Act of 2003 (H bill would affect the amount that a beneficiary would pay annually for prescription drugs.
Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits
This report examines these proposals as well as the “Medicare Rx Drug Benefit and Discount Act of 2003,” which was introduced by Representative Charles Rangel, the ranking member of the House Ways and Means Committee. Specifically, this report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs.
Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits
This report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs. In addition, this report gives examples of how annual cost-sharing would differ for beneficiaries with various levels of total prescription drug spending in 2006 under the plans.
Medicare Prescription Drug and Reform Legislation
This report describes the major features of S. 1, as ordered reported, and the measure to be considered by the House Ways and Means Committee, H.R. 2473, as ordered reported.
Overview of the Medicare Prescription Drug and Reform Legislation
No Description Available.
Overview of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
No Description Available.
Medicare Prescription Drug Provisions of S.1, as Passed by the Senate, and H.R. 1, as Passed by the House
This report discusses differences in the specifics of the prescription drug provisions in S. 1 and H.R. 1 and provides a side-by-side comparison of the Title I provisions of both bills.
The Hatch-Waxman Act: Proposed Legislative Changes
No Description Available.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report presents legislative changes affecting Pharmaceutical Patents related to the Hatch-Waxman Act.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on the Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
Products Liability: A Legal Overview
No Description Available.
The Cost of Prescription Drugs for the Uninsured Elderly and Legislative Approaches
The purpose of this report is to explain why many of those who are least able to afford high drug costs are those who are most frequently charged the most. This report describes the basic economic theory underlying price differentiation and, in the context of the pharmaceutical market, analyzes the role and behavior of pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and retail pharmacies, respectively. It also looks at a number of the criticisms that have been made of the practice of differential pricing. Finally, this report discusses various policy approaches aimed at assisting the elderly to purchase prescription drugs.
Firestone Tire Recall: NHTSA, Industry, and Congressional Responses
This report discusses the scope and nature of the safety challenge associated with the Firestone tire recall, and summarizes NHTSA’s defect investigations process (as of the end of the 106th Congress) and several relevant actions that NHTSA has taken to date. Second, some of the key efforts of Ford Motor Company (Ford) and Bridgestone/Firestone Inc. (Firestone) to deal with this challenge and associated economic impacts of the reported tire failures, and the recall are summarized
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
Medicare: Major Prescription Drug Provisions of Selected Bills
No Description Available.
Importing Prescription Drugs
No Description Available.
Importing Prescription Drugs
No Description Available.
Prescription Drug Importation and Internet Sales: A Legal Overview
No Description Available.
Importing Prescription Drugs: Objectives, Options, and Outlook
No Description Available.
Asbestos Compensation Act of 2000
This report summarizes H.R. 1283, 106th Congress, the Asbestos Compensation Act of 2000, as ordered to be reported with amendments by the House Committee on the Judiciary on March 16, 2000. The bill would create an administrative procedure for asbestos liability claims.
Prescription Drugs: Importation for Personal Use
No Description Available.
Identity Theft and the Fair Credit Reporting Act: An Analysis of
This report provides information about An Analysis of on Identity Theft and the Fair Credit Reporting Act. This report will provide a brief summary of the fair credit reporting act provisions in question, as well as an analysis of the recent supreme court decisions.
Back to Top of Screen